Cambridge Investment Research Advisors, Inc. Alaunos Therapeutics, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.9 Billion
Q4 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	BUY	$0.41 - $1.24 $5,852 - $17,701	14,275 New	14,275 $17,000
Q4 2020 Feb 04, 2021	SELL	$2.09 - $3.09 $24,396 - $36,069	-11,673 Closed	0 $0
Q3 2020 Oct 29, 2020	BUY	$2.39 - $3.43 $27,898 - $40,038	11,673 New	11,673 $29,000
Q3 2018 Nov 02, 2018	SELL	$2.26 - $3.27 $110,299 - $159,592	-48,805 Closed	0 $0
Q2 2018 Aug 10, 2018	SELL	$3.02 - $4.94 $4,327 - $7,079	-1,433 Reduced 2.85%	48,805 $0
Q1 2018 May 09, 2018	BUY	$3.46 - $5.14 $3,466 - $5,150	1,002 Added 2.04%	50,238 $0
Q4 2017 Feb 22, 2018	BUY	$4.0 - $6.54 $1,224 - $2,001	306 Added 0.63%	49,236 $0
Q3 2017 Nov 07, 2017	BUY	$4.99 - $6.57 $32,435 - $42,705	6,500 Added 15.32%	48,930 $300,000
Q2 2017 Aug 08, 2017	BUY	N/A	42,430	42,430 $264,000

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $322M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account